These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12751133)

  • 1. Regression of left ventricular hypertrophy after treatment of hypertension: comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes.
    Tse HF; Cheung BM; Ng W; Chan JK; Devereux RB; Lau CP
    J Card Fail; 2003 Apr; 9(2):122-7. PubMed ID: 12751133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.
    Devereux RB; Palmieri V; Sharpe N; De Quattro V; Bella JN; de Simone G; Walker JF; Hahn RT; Dahlöf B
    Circulation; 2001 Sep; 104(11):1248-54. PubMed ID: 11551875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).
    Devereux RB; Dahlof B; Levy D; Pfeffer MA
    Am J Cardiol; 1996 Jul; 78(1):61-5. PubMed ID: 8712120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study.
    Perdrix L; Mansencal N; Cocheteux B; Chatellier G; Bissery A; Diebold B; Mousseaux E; Abergel E
    Arch Cardiovasc Dis; 2011 May; 104(5):343-51. PubMed ID: 21693371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
    J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril.
    Galderisi M; Celentano A; Garofalo M; Tammaro P; Oliviero M; Petrocelli A; de Divitiis O
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):312-6. PubMed ID: 7921533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three-dimensional echocardiographic findings to those of magnetic resonance imaging for determination of left ventricular mass in patients with ischemic and non-ischemic cardiomyopathy.
    Kusunose K; Kwon DH; Motoki H; Flamm SD; Marwick TH
    Am J Cardiol; 2013 Aug; 112(4):604-11. PubMed ID: 23768466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
    Ueno H; Takata M; Tomita S; Oh-hashi S; Yasumoto K; Inoue H
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):643-8. PubMed ID: 9388047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular myocardial mass determination by contrast enhanced colour Doppler compared with magnetic resonance imaging.
    Bezante GP; Chen X; Molinari G; Valbusa A; Deferrari L; Sebastiani V; Yokoyama N; Steinmetz S; Barsotti A; Schwarz KQ
    Heart; 2005 Jan; 91(1):38-43. PubMed ID: 15604332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A reduction of left ventricular hypertrophy and an improvement in diastolic function after therapy with nifedipine retard in patients with hypertensive cardiopathy].
    Amici E; Patruno N; Natale E; Marsocci A; Gambelli G
    Cardiologia; 1993 Sep; 38(9):585-91. PubMed ID: 8287388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.
    Aurigemma GP; Devereux RB; Wachtell K; Palmieri V; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    Am J Hypertens; 2003 Mar; 16(3):180-6. PubMed ID: 12620695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepancies in Left Ventricular Mass Calculation Based on Echocardiography and Cardiovascular Magnetic Resonance Measurements in Patients with Left Ventricular Hypertrophy.
    Seo HY; Lee SP; Park JB; Lee JM; Park EA; Chang SA; Kim HK; Park SJ; Lee W; Kim YJ; Lee SC; Park SW; Sohn DW; Choe YH
    J Am Soc Echocardiogr; 2015 Oct; 28(10):1194-1203, e2. PubMed ID: 26194306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
    Boydak B; Nalbantgil S; Yilmaz H; Zoghi M; Ozerkan F; Nalbantgil I; Onder R
    Saudi Med J; 2004 Dec; 25(12):1975-8. PubMed ID: 15711679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension.
    Gosse P; Guez D; Guéret P; Dubourg O; Beauchet A; de Cordoüe A; Barrandon S
    J Hypertens; 1998 Apr; 16(4):531-5. PubMed ID: 9797199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
    Bella JN; Palmieri V; Wachtell K; Liu JE; Gerdts E; Nieminen MS; Koren MJ; Zabalgoitia M; Wright JT; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):411-6. PubMed ID: 15042116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.